GURUFOCUS.COM » STOCK LIST » USA » NAS » Incyte Corp (NAS:INCY) » Definitions » Shiller PE Ratio
Switch to:

Incyte Shiller PE Ratio

: 163.84 (As of Today)
View and export this data going back to 1993. Start your Free Trial

As of today (2022-08-10), Incyte's current share price is $73.73. Incyte's E10 for the quarter that ended in Jun. 2022 was $0.45. Incyte's Shiller PE Ratio for today is 163.84.

The historical rank and industry rank for Incyte's Shiller PE Ratio or its related term are showing as below:

INCY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 156.44   Med: 206.97   Max: 249.6
Current: 165.67

During the past years, Incyte's highest Shiller PE Ratio was 249.60. The lowest was 156.44. And the median was 206.97.

INCY's Shiller PE Ratio is ranked worse than
90.83% of 120 companies
in the Biotechnology industry
Industry Median: 43.24 vs INCY: 165.67

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Incyte's adjusted earnings per share data for the three months ended in Jun. 2022 was $0.720. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.45 for the trailing ten years ended in Jun. 2022.

Shiller PE for Stocks: The True Measure of Stock Valuation


Incyte Shiller PE Ratio Historical Data

The historical data trend for Incyte's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Shiller PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 245.29

Incyte Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Shiller PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 245.29 214.25 170.70

Competitive Comparison

For the Biotechnology subindustry, Incyte's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Incyte Shiller PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Incyte's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Incyte's Shiller PE Ratio falls into.



Incyte Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Incyte's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=73.73/0.45
=163.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte's E10 for the quarter that ended in Jun. 2022 is calculated as:

For example, Incyte's adjusted earnings per share data for the three months ended in Jun. 2022 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2022 (Change)*Current CPI (Jun. 2022)
=0.72/123.3228*123.3228
=0.720

Current CPI (Jun. 2022) = 123.3228.

Incyte Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201209 -0.170 97.633 -0.215
201212 0.140 96.871 0.178
201303 -0.120 98.209 -0.151
201306 -0.020 98.518 -0.025
201309 -0.140 98.790 -0.175
201312 -0.260 98.326 -0.326
201403 -0.210 99.695 -0.260
201406 -0.220 100.560 -0.270
201409 0.330 100.428 0.405
201412 -0.220 99.070 -0.274
201503 -0.110 99.621 -0.136
201506 0.050 100.684 0.061
201509 -0.220 100.392 -0.270
201512 0.290 99.792 0.358
201603 0.120 100.470 0.147
201606 0.180 101.688 0.218
201609 0.190 101.861 0.230
201612 0.050 101.863 0.061
201703 -0.960 102.862 -1.151
201706 -0.060 103.349 -0.072
201709 0.170 104.136 0.201
201712 -0.710 104.011 -0.842
201803 -0.190 105.290 -0.223
201806 0.240 106.317 0.278
201809 0.140 106.507 0.162
201812 0.320 105.998 0.372
201903 0.470 107.251 0.540
201906 0.480 108.070 0.548
201909 0.590 108.329 0.672
201912 0.510 108.420 0.580
202003 -3.330 108.902 -3.771
202006 1.320 108.767 1.497
202009 -0.070 109.815 -0.079
202012 0.680 109.897 0.763
202103 0.240 111.754 0.265
202106 0.670 114.631 0.721
202109 0.820 115.734 0.874
202112 2.540 117.630 2.663
202203 0.170 121.301 0.173
202206 0.720 123.323 0.720

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Incyte  (NAS:INCY) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Incyte Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Incyte's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Incyte Business Description

Incyte logo
Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Executives
Tray Thomas officer: Principal Accounting Officer C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Brawley Otis W director 5203 BRISTOL INDUSTRIAL WAY BUFORD GA 30518
High Katherine A director 3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104
Harrigan Edmund director
Morrissey Michael James officer: EVP, Head of Tech. Operations IN CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803
Dickinson Jonathan Elliott officer: EVP, General Manager, Europe CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803
Stamoulis Christiana officer: EVP & Chief Financial Officer C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST CAMBRIDGE MA 02139
Dhanak Dashyant officer: EVP & Chief Scientific Officer C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Pasquale Maria E officer: EVP & General Counsel C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Fouse Jacqualyn A director C/O DICK'S SPORTING GOODS 345 COURT STREET CORAOPOLIS PA 15108
Iyengar Vijay K officer: EVP GPS, BD, & Licensing 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Stein Steven H officer: EVP & Chief Medical Officer 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Trower Paul officer: VP, Finance & Prin Acc Officer 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Clancy Paul J director C/O BIOGEN IDEC INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142
Bienaime Jean Jacques director 925 PAGE MILL ROAD PALO ALTO CA 94304

Incyte Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)